ProfileGDS5678 / 1434791_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 76% 76% 76% 80% 75% 74% 74% 76% 75% 75% 76% 79% 77% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.0778276
GSM967853U87-EV human glioblastoma xenograft - Control 25.0710776
GSM967854U87-EV human glioblastoma xenograft - Control 35.0750876
GSM967855U87-EV human glioblastoma xenograft - Control 45.7414580
GSM967856U87-EV human glioblastoma xenograft - Control 55.0273975
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.7662574
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.7105374
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.0443976
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.0355775
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.0599775
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.0538976
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.4920779
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2370277
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3232578